[Skip to Content]
[Skip to Content Landing]
Correspondence
May 2010

Acneiform Eruption in a Patient Receiving Bevacizumab for Glioblastoma Multiforme

Author Affiliations
 

Copyright 2010 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2010

Arch Dermatol. 2010;146(5):577. doi:10.1001/archdermatol.2010.68

Bevacizumab, a humanized monoclonal antibody targeting vascular endothelial growth factor (VEGF), is used in the treatment of several cancers, macular degeneration, and proliferative diabetic retinopathy as a means of limiting angiogenesis, a hallmark feature of these diseases. Nonspecific skin eruption has been reported in some patients receiving bevacizumab, and recently, bevacizumab-associated acneiform eruption was reported in the treatment of colon cancer (systemic administration) and macular degeneration (intravitreal administration).1-3 The eruption in these patients was strikingly similar to that characterized in patients treated with epidermal growth factor receptor (EGFR) inhibitors.1-4 We report a case of bevacizumab-induced acneiform eruption in a patient with glioblastoma multiforme.

×